- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acumen Pharmaceuticals Inc (ABOS)
Assess today's live Acumen Pharmaceuticals Inc (ABOS) share price, performance and insights using our live NASDAQ: ABOS stock exchange data.
Analyse the historical data and Acumen Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Acumen Pharmaceuticals share price buy/sell indicators using real-time data (or discuss the Acumen Pharmaceuticals (ABOS) stock price today with other investors in the Acumen Pharmaceuticals NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ABOS share price (ISIN: US00509G2093) to enhance your trading decisions with our free investment tools and resources.
What Is the Acumen Pharmaceuticals Inc Share Price Today?
The Acumen Pharmaceuticals share price today is 2.170.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc
The stock symbol (or 'ticker') for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Acumen Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Acumen Pharmaceuticals share price buy/sell indicators using real-time data (or discuss the Acumen Pharmaceuticals (ABOS) stock price today with other investors in the Acumen Pharmaceuticals NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ABOS share price (ISIN: US00509G2093) to enhance your trading decisions with our free investment tools and resources.
What Is the Acumen Pharmaceuticals Inc Share Price Today?
The Acumen Pharmaceuticals share price today is 2.170.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc
The stock symbol (or 'ticker') for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.120
2.320
52 wk Range
0.855
2.460
ABOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1202.320
52 wk Range
0.8552.460
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABOS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
6.400
Upside
+194.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Acumen Pharmaceuticals Company Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.68 missed forecast by 33.33%, stock dipped 1.41% to $1.40 in premarket trading
- R&D expenses rose to $37.1M, cash reserves of $166.2M expected to support operations into early 2027
- Collaboration with JCR Pharmaceuticals continues, offering potential milestone payments up to $555M
- Top-line results from ALPITUDE AD phase two study expected in late 2026, crucial for future performance
- Focus on blood-based biomarkers and innovative brain delivery technology to advance Alzheimer's treatment
Last Updated: 12/08/2025, 14:10
Read Full TranscriptCompare ABOS to Peers and Sector
Metrics to compare | ABOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −2.4x | −0.6x | |
PEG Ratio | 0.02 | 0.08 | 0.00 | |
Price/Book | 1.4x | 4.0x | 2.6x | |
Price / LTM Sales | - | 10.7x | 3.2x | |
Upside (Analyst Target) | 176.5% | 31.7% | 41.8% | |
Fair Value Upside | Unlock | 1.1% | 5.1% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.400
(+194.93% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.44 / -0.603
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Acumen Pharmaceuticals (ABOS) Share Price Today?
The live Acumen Pharmaceuticals share price today is 2.170
What Stock Exchange Does Acumen Pharmaceuticals (ABOS) Trade On?
Acumen Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Acumen Pharmaceuticals?
The stock symbol (also called a 'ticker') for Acumen Pharmaceuticals is "ABOS."
What Is the Current Acumen Pharmaceuticals Market Cap?
As of today, Acumen Pharmaceuticals market capitalisation is 132.05M.
What Is Acumen Pharmaceuticals's (ABOS) Earnings Per Share (TTM)?
The Acumen Pharmaceuticals EPS is currently -2.21 (Trailing Twelve Months).
When Is the Next Acumen Pharmaceuticals Earnings Date?
Acumen Pharmaceuticals's next earnings report will be released on 29 Mar 2026.
Is ABOS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Acumen Pharmaceuticals moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Acumen Pharmaceuticals Stock Split?
Acumen Pharmaceuticals has split 0 times. (See the ABOS stock split history page for full effective split date and price information.)
How Many Employees Does Acumen Pharmaceuticals Have?
Acumen Pharmaceuticals has 61 employees.
What is the current trading status of Acumen Pharmaceuticals (ABOS)?
As of 24 Dec 2025, Acumen Pharmaceuticals (ABOS) is trading at a price of 2.170, with a previous close of 2.280. The stock has fluctuated within a day range of 2.120 to 2.320, while its 52-week range spans from 0.855 to 2.460.
What Is Acumen Pharmaceuticals (ABOS) Price Target According to Analysts?
The average 12-month price target for Acumen Pharmaceuticals is USD6.4, with a high estimate of USD10 and a low estimate of USD4. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +194.93% Upside potential.
What Is the ABOS Premarket Price?
ABOS's last pre-market stock price is 2.360. The pre-market share volume is 3,000.000, and the stock has decreased by 0.080, or 3.510%.
What Is the ABOS After Hours Price?
ABOS's last after hours stock price is 2.240, the stock has decreased by 0.070, or 3.230%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.